SCHEMBL1871966

SCHEMBL1871966

Cc1cccc(S(=O)(=O)N(C)/N=C/c2cnc3c(C)cc(-c4cccnc4)cn23)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
FLT3 P36888 4/20 0.40
PIK3CA P42336 4/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.37
DYRK3 O43781 1/20 0.37
CDK2 P24941 1/20 0.37
CSNK1E P49674 1/20 0.37
CLK1 P49759 1/20 0.37
CLK2 P49760 1/20 0.37
CLK3 P49761 1/20 0.37
GSK3B P49841 1/20 0.37
CDK7 P50613 1/20 0.37
CDK5 Q00535 1/20 0.37
DYRK1A Q13627 1/20 0.37
MELK Q14680 1/20 0.37
CDK5R1 Q15078 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1871967 1.00 CYP11B1 (0.40) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1865575 0.92 FLT3 (0.42) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1865579 0.92 FLT3 (0.42) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1867484 0.91 CYP11B1 (0.51) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1867481 0.91 CYP11B1 (0.51) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1873740 0.90 FLT3 (0.46) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1867788 0.90 MC4R (0.44) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1873738 0.90 FLT3 (0.46) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1867785 0.90 MC4R (0.44) CYP11B1CYP11B2FLT3PIK3CACCNT1
SCHEMBL1869539 0.89 PIK3CA (0.48) FLT3PIK3CACCNT1CDK9PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741932-B2 Imidazopyridine derivatives Piramal Enterprises Limited (IN) 2014-06-03 US claimed
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-09-13 US claimed
US-8741932-B2 Imidazopyridine derivatives Piramal Enterprises Limited (IN) 2014-06-03 US disclosed
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-09-13 US disclosed
EP-2496577-A1 IMIDAZOPYRIDINE DERIVATIVES Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
WO-2011055320-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES IL6, IL6ST, STAT3 CYP11B1 2145/4885CYP11B2 2330/4885FLT3 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.